secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004557
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025
--------------------------------------------------------------------------------

- Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.
- Full data from Phase 2 VERONA trial of DURAVYU in DME expected 1Q 2025; interim data showed BCVA gain +8.9 letters and CST improvement.
- Cash and investments ~$370M at Dec 31, 2024; cash runway into 2027 beyond Phase 3 wet AMD topline data expected in 2026.
- Appointed retina specialist Reginald J. Sanders, M.D., FASRS to Board of Directors.
- Opened new 40,000+ sq ft cGMP manufacturing facility in Northbridge, MA to support commercial readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025004557/0000950170-25-004557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025004557/eypt-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer